These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

320 related articles for article (PubMed ID: 22784116)

  • 1. Blockade of lymphocyte chemotaxis in visceral graft-versus-host disease.
    Reshef R; Luger SM; Hexner EO; Loren AW; Frey NV; Nasta SD; Goldstein SC; Stadtmauer EA; Smith J; Bailey S; Mick R; Heitjan DF; Emerson SG; Hoxie JA; Vonderheide RH; Porter DL
    N Engl J Med; 2012 Jul; 367(2):135-45. PubMed ID: 22784116
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical and immunologic impact of CCR5 blockade in graft-versus-host disease prophylaxis.
    Moy RH; Huffman AP; Richman LP; Crisalli L; Wang XK; Hoxie JA; Mick R; Emerson SG; Zhang Y; Vonderheide RH; Porter DL; Reshef R
    Blood; 2017 Feb; 129(7):906-916. PubMed ID: 28057639
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Extended CCR5 Blockade for Graft-versus-Host Disease Prophylaxis Improves Outcomes of Reduced-Intensity Unrelated Donor Hematopoietic Cell Transplantation: A Phase II Clinical Trial.
    Reshef R; Ganetsky A; Acosta EP; Blauser R; Crisalli L; McGraw J; Frey NV; Hexner EO; Hoxie JA; Loren AW; Luger SM; Mangan J; Stadtmauer EA; Mick R; Vonderheide RH; Porter DL
    Biol Blood Marrow Transplant; 2019 Mar; 25(3):515-521. PubMed ID: 30315941
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Pharmacokinetic and Pharmacodynamic Study of Maraviroc as Acute Graft-versus-Host Disease Prophylaxis in Pediatric Allogeneic Stem Cell Transplant Recipients with Nonmalignant Diagnoses.
    Khandelwal P; Fukuda T; Mizuno K; Teusink-Cross A; Mehta PA; Marsh RA; Kashuba ADM; Vinks AA; Davies SM
    Biol Blood Marrow Transplant; 2016 Oct; 22(10):1829-1835. PubMed ID: 27498124
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Blockade of CCR5 to protect the liver graft in HIV/HCV co-infected patients.
    Haïm-Boukobza S; Balabanian K; Teicher E; Bourgeade M; Perlemuter G; Roque-Afonso AM; Duclos-Vallee JC
    J Hepatol; 2013 Sep; 59(3):613-5. PubMed ID: 23583366
    [No Abstract]   [Full Text] [Related]  

  • 6. Blockade of chemotaxis in graft-versus-host disease.
    Davies JK; Gribben JG
    N Engl J Med; 2012 Oct; 367(17):1667; author reply 1667-8. PubMed ID: 23094739
    [No Abstract]   [Full Text] [Related]  

  • 7. Prophylaxis of acute graft-versus-host disease by CCR5 blockade combined with cyclosporine A in a murine model.
    Yuan J; Ren HY; Shi YJ; Liu W
    Inflamm Res; 2015 Feb; 64(2):137-44. PubMed ID: 25556580
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacodynamic Monitoring Predicts Outcomes of CCR5 Blockade as Graft-versus-Host Disease Prophylaxis.
    Huffman AP; Richman LP; Crisalli L; Ganetsky A; Porter DL; Vonderheide RH; Reshef R
    Biol Blood Marrow Transplant; 2018 Mar; 24(3):594-599. PubMed ID: 29061535
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CCR5 inhibitor as novel acute graft versus host disease prophylaxis in children and young adults undergoing allogeneic stem cell transplant: results of the phase II study.
    Khandelwal P; Fukuda T; Teusink-Cross A; Kashuba ADM; Lane A; Mehta PA; Marsh RA; Jordan MB; Grimley MS; Myers KC; Nelson AS; El-Bietar J; Chandra S; Bleesing JJ; Krupski MC; Davies SM
    Bone Marrow Transplant; 2020 Aug; 55(8):1552-1559. PubMed ID: 32273585
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Addition of sirolimus to standard cyclosporine plus mycophenolate mofetil-based graft-versus-host disease prophylaxis for patients after unrelated non-myeloablative haemopoietic stem cell transplantation: a multicentre, randomised, phase 3 trial.
    Sandmaier BM; Kornblit B; Storer BE; Olesen G; Maris MB; Langston AA; Gutman JA; Petersen SL; Chauncey TR; Bethge WA; Pulsipher MA; Woolfrey AE; Mielcarek M; Martin PJ; Appelbaum FR; Flowers MED; Maloney DG; Storb R
    Lancet Haematol; 2019 Aug; 6(8):e409-e418. PubMed ID: 31248843
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chemokine receptor blockade in graft-versus-host disease.
    Brower V
    Lancet Oncol; 2012 Aug; 13(8):e333. PubMed ID: 23024998
    [No Abstract]   [Full Text] [Related]  

  • 13. CCR5 blockade combined with cyclosporine A attenuates liver GVHD by impairing T cells function.
    Tang B; Ren H; Liu H; Shi Y; Liu W; Dong Y; Yin Y; Miao S
    Inflamm Res; 2016 Nov; 65(11):917-924. PubMed ID: 27423909
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Modified donor lymphocyte infusion-associated acute graft-versus-host disease after haploidentical T-cell-replete hematopoietic stem cell transplantation: incidence and risk factors.
    Yan CH; Liu DH; Xu LP; Liu KY; Zhao T; Wang Y; Chen H; Chen YH; Han W; Huang XJ
    Clin Transplant; 2012; 26(6):868-76. PubMed ID: 22432715
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of two different doses of rabbit anti-T-lymphocyte globulin to prevent graft-versus-host disease in children with haematological malignancies transplanted from an unrelated donor: a multicentre, randomised, open-label, phase 3 trial.
    Locatelli F; Bernardo ME; Bertaina A; Rognoni C; Comoli P; Rovelli A; Pession A; Fagioli F; Favre C; Lanino E; Giorgiani G; Merli P; Pagliara D; Prete A; Zecca M
    Lancet Oncol; 2017 Aug; 18(8):1126-1136. PubMed ID: 28705454
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro effect of anti-human immunodeficiency virus CCR5 antagonist maraviroc on chemotactic activity of monocytes, macrophages and dendritic cells.
    Rossi R; Lichtner M; De Rosa A; Sauzullo I; Mengoni F; Massetti AP; Mastroianni CM; Vullo V
    Clin Exp Immunol; 2011 Nov; 166(2):184-90. PubMed ID: 21985364
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Partial T-cell depletion improves the composite endpoint graft-versus-host disease-free, relapse-free survival after allogeneic hematopoietic stem cell transplantation.
    Simonetta F; Masouridi-Levrat S; Beauverd Y; Tsopra O; Tirefort Y; Koutsi A; Stephan C; Polchlopek-Blasiak K; Pradier A; Dantin C; Ansari M; Roosnek E; Chalandon Y
    Leuk Lymphoma; 2018 Mar; 59(3):590-600. PubMed ID: 28679328
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alloreactive T Cells Display a Distinct Chemokine Profile in Response to Conditioning in Xenogeneic GVHD Models.
    Kawasaki Y; Sato K; Nakano H; Hayakawa H; Izawa J; Takayama N; Mashima K; Oh I; Minakata D; Yamasaki R; Morita K; Ashizawa M; Yamamoto C; Hatano K; Fujiwara SI; Ohmine K; Muroi K; Ito R; Hayakawa M; Ohmori T; Kanda Y
    Transplantation; 2019 Sep; 103(9):1834-1843. PubMed ID: 31461746
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cannabidiol for the Prevention of Graft-versus-Host-Disease after Allogeneic Hematopoietic Cell Transplantation: Results of a Phase II Study.
    Yeshurun M; Shpilberg O; Herscovici C; Shargian L; Dreyer J; Peck A; Israeli M; Levy-Assaraf M; Gruenewald T; Mechoulam R; Raanani P; Ram R
    Biol Blood Marrow Transplant; 2015 Oct; 21(10):1770-5. PubMed ID: 26033282
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dipeptidyl Peptidase 4 Inhibition for Prophylaxis of Acute Graft-versus-Host Disease.
    Farag SS; Abu Zaid M; Schwartz JE; Thakrar TC; Blakley AJ; Abonour R; Robertson MJ; Broxmeyer HE; Zhang S
    N Engl J Med; 2021 Jan; 384(1):11-19. PubMed ID: 33406328
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.